CD274 and cervical carcinoma: As such, the study by Schmidt et al. [37] revealed that among cervical cancer treatments, pembrolizumab combined with chemotherapy and bevacizumab significantly increases overall survival, highlighting the importance of selecting patients based on PD-L1 status due to the lack of response in PD-L1 negative individuals.